{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T15:40:09Z","timestamp":1795275609366,"version":"4.10.3"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tightly orchestrated programmed cell death (PCD) signalling events occur during normal neuronal development in a spatially and temporally restricted manner to establish the neural architecture and shaping the CNS. Abnormalities in PCD signalling cascades, such as apoptosis, necroptosis, pyroptosis, ferroptosis, and cell death associated with autophagy as well as in unprogrammed necrosis can be observed in the pathogenesis of various neurological diseases. These cell deaths can be activated in response to various forms of cellular stress (exerted by intracellular or extracellular stimuli) and inflammatory processes. Aberrant activation of PCD pathways is a common feature in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease, resulting in unwanted loss of neuronal cells and function. Conversely, inactivation of PCD is thought to contribute to the development of brain cancers and to impact their response to therapy. For many neurodegenerative diseases and brain cancers current treatment strategies have only modest effect, engendering the need for investigations into the origins of these diseases. With many diseases of the brain displaying aberrations in PCD pathways, it appears that agents that can either inhibit or induce PCD may be critical components of future therapeutic strategies. The development of such therapies will have to be guided by preclinical studies in animal models that faithfully mimic the human disease. In this review, we briefly describe PCD and unprogrammed cell death processes and the roles they play in contributing to neurodegenerative diseases or tumorigenesis in the brain. We also discuss the interplay between distinct cell death signalling cascades and disease pathogenesis and describe pharmacological agents targeting key players in the cell death signalling pathways that have progressed through to clinical trials.<\/jats:p>","DOI":"10.1038\/s41418-021-00814-y","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T10:09:43Z","timestamp":1623060583000},"page":"2029-2044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":711,"title":["Molecular mechanisms of cell death in neurological diseases"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-2788","authenticated-orcid":false,"given":"Diane","family":"Moujalled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-4891","authenticated-orcid":false,"given":"Andreas","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0798-5338","authenticated-orcid":false,"given":"Jeffrey R.","family":"Liddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"814_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/bjc.1972.33","volume":"26","author":"JF Kerr","year":"1972","unstructured":"Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239\u201357.","journal-title":"Br J Cancer."},{"key":"814_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-cancerbio-030419-033510","volume":"4","author":"GL Kelly","year":"2020","unstructured":"Kelly GL, Strasser A. Toward targeting antiapoptotic MCL-1 for cancer therapy. Annu Rev Cancer Biol. 2020;4:299\u2013313.","journal-title":"Annu Rev Cancer Biol"},{"key":"814_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0092-8674(00)00187-2","volume":"103","author":"DC Huang","year":"2000","unstructured":"Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell. 2000;103:839\u201342.","journal-title":"Cell."},{"key":"814_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.cell.2019.04.024","volume":"177","author":"DR Green","year":"2019","unstructured":"Green DR. The coming decade of cell death research: five riddles. Cell. 2019;177:1094\u2013107.","journal-title":"Cell."},{"key":"814_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"814_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1097-2765(02)00482-3","volume":"9","author":"Y Shi","year":"2002","unstructured":"Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9:459\u201370.","journal-title":"Mol Cell"},{"key":"814_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0301-2115(95)02261-9","volume":"64","author":"C Haanen","year":"1996","unstructured":"Haanen C, Vermes I. Apoptosis: programmed cell death in fetal development. Eur J Obstet Gynecol Reprod Biol. 1996;64:129\u201333.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"814_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0166-2236(00)01581-2","volume":"23","author":"CY Kuan","year":"2000","unstructured":"Kuan CY, Roth KA, Flavell RA, Rakic P. Mechanisms of programmed cell death in the developing brain. Trends Neurosci. 2000;23:291\u20137.","journal-title":"Trends Neurosci"},{"key":"814_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/s41418-018-0225-1","volume":"26","author":"LC Fogarty","year":"2019","unstructured":"Fogarty LC, Flemmer RT, Geizer BA, Licursi M, Karunanithy A, Opferman JT, et al. Mcl-1 and Bcl-xL are essential for survival of the developing nervous system. Cell Death Differ. 2019;26:1501\u201315.","journal-title":"Cell Death Differ"},{"key":"814_CR10","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1523\/JNEUROSCI.4940-07.2008","volume":"28","author":"N Arbour","year":"2008","unstructured":"Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, Cheung EC, et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J Neurosci. 2008;28:6068\u201378.","journal-title":"J Neurosci"},{"key":"814_CR11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1126\/science.7878471","volume":"267","author":"N Motoyama","year":"1995","unstructured":"Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 1995;267:1506\u201310.","journal-title":"Science."},{"key":"814_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2018.04.036","volume":"173","author":"FFS Ke","year":"2018","unstructured":"Ke FFS, Vanyai HK, Cowan AD, Delbridge ARD, Whitehead L, Grabow S, et al. Embryogenesis and adult life in the absence of intrinsic apoptosis effectors BAX, BAK, and BOK. Cell. 2018;173:1217\u201330 e17.","journal-title":"Cell."},{"key":"814_CR13","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1016\/j.celrep.2018.08.048","volume":"24","author":"S Grabow","year":"2018","unstructured":"Grabow S, Kueh AJ, Ke F, Vanyai HK, Sheikh BN, Dengler MA, et al. Subtle changes in the levels of BCL-2 proteins cause severe craniofacial abnormalities. Cell Rep. 2018;24:3285\u201395 e4.","journal-title":"Cell Rep."},{"key":"814_CR14","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/j.1582-4934.2008.00402.x","volume":"12","author":"AM Gorman","year":"2008","unstructured":"Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med. 2008;12:2263\u201380.","journal-title":"J Cell Mol Med."},{"key":"814_CR15","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15252\/emmm.201302627","volume":"6","author":"SK Carlsson","year":"2014","unstructured":"Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 2014;6:1359\u201370.","journal-title":"EMBO Mol Med"},{"key":"814_CR16","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918\u201334.","journal-title":"Cell."},{"key":"814_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787\u201395.","journal-title":"Nature."},{"key":"814_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/aps.2009.24","volume":"30","author":"XX Dong","year":"2009","unstructured":"Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharm Sin. 2009;30:379\u201387.","journal-title":"Acta Pharm Sin"},{"key":"814_CR19","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","volume":"21","author":"C Soto","year":"2018","unstructured":"Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332\u201340.","journal-title":"Nat Neurosci."},{"key":"814_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0092-8674(00)00003-9","volume":"102","author":"DR Green","year":"2000","unstructured":"Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102:1\u20134.","journal-title":"Cell."},{"key":"814_CR21","first-page":"2922","volume":"15","author":"X Wang","year":"2001","unstructured":"Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922\u201333.","journal-title":"Genes Dev"},{"key":"814_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.cdd.4400998","volume":"9","author":"H Puthalakath","year":"2002","unstructured":"Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 2002;9:505\u201312.","journal-title":"Cell Death Differ"},{"key":"814_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393\u2013403.","journal-title":"Mol Cell"},{"key":"814_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.immuni.2009.01.001","volume":"30","author":"A Strasser","year":"2009","unstructured":"Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180\u201392.","journal-title":"Immunity."},{"key":"814_CR25","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798\u2013811.","journal-title":"Oncogene."},{"key":"814_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942\u201355.","journal-title":"Lancet."},{"key":"814_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40263-016-0317-8","volume":"30","author":"D Moujalled","year":"2016","unstructured":"Moujalled D, White AR. Advances in the development of disease-modifying treatments for amyotrophic lateral sclerosis. CNS Drugs. 2016;30:227\u201343.","journal-title":"CNS Drugs."},{"key":"814_CR28","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","volume":"7","author":"L Ferraiuolo","year":"2011","unstructured":"Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:616\u201330.","journal-title":"Nat Rev Neurol"},{"key":"814_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neuron.2004.06.021","volume":"43","author":"P Pasinelli","year":"2004","unstructured":"Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43:19\u201330.","journal-title":"Neuron."},{"key":"814_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.neuron.2006.09.018","volume":"52","author":"S Boillee","year":"2006","unstructured":"Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39\u201359.","journal-title":"Neuron."},{"key":"814_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1006\/nbdi.2000.0295","volume":"7","author":"JL Gonzalez de Aguilar","year":"2000","unstructured":"Gonzalez de Aguilar JL, Gordon JW, Rene F, de Tapia M, Lutz-Bucher B, Gaiddon C, et al. Alteration of the Bcl-x\/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiol Dis. 2000;7:406\u201315.","journal-title":"Neurobiol Dis."},{"key":"814_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ana.410400307","volume":"40","author":"X Mu","year":"1996","unstructured":"Mu X, He J, Anderson DW, Trojanowski JQ, Springer JE. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann Neurol. 1996;40:379\u201386.","journal-title":"Ann Neurol"},{"key":"814_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1600-0404.1999.tb00403.x","volume":"100","author":"T Ekegren","year":"1999","unstructured":"Ekegren T, Grundstrom E, Lindholm D, Aquilonius SM. Upregulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons. Acta Neurol Scand. 1999;100:317\u201321.","journal-title":"Acta Neurol Scand"},{"key":"814_CR34","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/sj.cdd.4402166","volume":"14","author":"C Hetz","year":"2007","unstructured":"Hetz C, Thielen P, Fisher J, Pasinelli P, Brown RH, Korsmeyer S, et al. The proapoptotic BCL-2 family member BIM mediates motoneuron loss in a model of amyotrophic lateral sclerosis. Cell Death Differ. 2007;14:1386\u20139.","journal-title":"Cell Death Differ"},{"key":"814_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1126\/science.288.5464.335","volume":"288","author":"M Li","year":"2000","unstructured":"Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288:335\u20139.","journal-title":"Science."},{"key":"814_CR36","doi-asserted-by":"publisher","first-page":"9119","DOI":"10.1523\/JNEUROSCI.20-24-09119.2000","volume":"20","author":"S Vukosavic","year":"2000","unstructured":"Vukosavic S, Stefanis L, Jackson-Lewis V, Guegan C, Romero N, Chen C, et al. Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2000;20:9119\u201325.","journal-title":"J Neurosci"},{"key":"814_CR37","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1172\/JCI42986","volume":"120","author":"NA Reyes","year":"2010","unstructured":"Reyes NA, Fisher JK, Austgen K, VandenBerg S, Huang EJ, Oakes SA. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest. 2010;120:3673\u20139.","journal-title":"J Clin Invest"},{"key":"814_CR38","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"814_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1096\/fj.04-2637fje","volume":"19","author":"Y Ohyagi","year":"2005","unstructured":"Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer\u2019s disease. FASEB J. 2005;19:255\u20137.","journal-title":"FASEB J"},{"key":"814_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1083\/jcb.200110119","volume":"156","author":"Y Zhang","year":"2002","unstructured":"Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002;156:519\u201329.","journal-title":"J Cell Biol"},{"key":"814_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0006-8993(97)01202-X","volume":"780","author":"Y Kitamura","year":"1998","unstructured":"Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer\u2019s disease. Brain Res. 1998;780:260\u20139.","journal-title":"Brain Res"},{"key":"814_CR42","doi-asserted-by":"publisher","first-page":"107839","DOI":"10.1016\/j.celrep.2020.107839","volume":"31","author":"G Park","year":"2020","unstructured":"Park G, Nhan HS, Tyan SH, Kawakatsu Y, Zhang C, Navarro M, et al. Caspase activation and caspase-mediated cleavage of APP is associated with amyloid beta-protein-induced synapse loss in Alzheimer\u2019s disease. Cell Rep. 2020;31:107839.","journal-title":"Cell Rep."},{"key":"814_CR43","doi-asserted-by":"publisher","first-page":"21011","DOI":"10.1074\/jbc.274.30.21011","volume":"274","author":"L Pellegrini","year":"1999","unstructured":"Pellegrini L, Passer BJ, Tabaton M, Ganjei JK, D\u2019Adamio L. Alternative, non-secretase processing of Alzheimer\u2019s beta-amyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem. 1999;274:21011\u20136.","journal-title":"J Biol Chem"},{"key":"814_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1046\/j.1471-4159.2003.02059.x","volume":"87","author":"DC Lu","year":"2003","unstructured":"Lu DC, Soriano S, Bredesen DE, Koo EH. Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem. 2003;87:733\u201341.","journal-title":"J Neurochem"},{"key":"814_CR45","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1046\/j.1471-4159.2003.02105.x","volume":"87","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Przedborski S, et al. Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington\u2019s disease. J Neurochem. 2003;87:1184\u201392.","journal-title":"J Neurochem"},{"key":"814_CR46","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1111\/j.1460-9568.2010.07215.x","volume":"31","author":"R Leon","year":"2010","unstructured":"Leon R, Bhagavatula N, Ulukpo O, McCollum M, Wei J. BimEL as a possible molecular link between proteasome dysfunction and cell death induced by mutant huntingtin. Eur J Neurosci. 2010;31:1915\u201325.","journal-title":"Eur J Neurosci"},{"key":"814_CR47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/hmg\/ddz275","volume":"29","author":"SL Roberts","year":"2020","unstructured":"Roberts SL, Evans T, Yang Y, Fu Y, Button RW, Sipthorpe RJ, et al. Bim contributes to the progression of Huntington\u2019s disease-associated phenotypes. Hum Mol Genet. 2020;29:216\u201327.","journal-title":"Hum Mol Genet"},{"key":"814_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00401-004-0957-5","volume":"109","author":"JC Vis","year":"2005","unstructured":"Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, et al. Expression pattern of apoptosis-related markers in Huntington\u2019s disease. Acta Neuropathol. 2005;109:321\u20138.","journal-title":"Acta Neuropathol"},{"key":"814_CR49","doi-asserted-by":"publisher","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A. Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2:a008888.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"814_CR50","doi-asserted-by":"publisher","first-page":"e99916","DOI":"10.15252\/embj.201899916","volume":"38","author":"JP Bernardini","year":"2019","unstructured":"Bernardini JP, Brouwer JM, Tan IK, Sandow JJ, Huang S, Stafford CA, et al. Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy. EMBO J. 2019;38:e99916.","journal-title":"EMBO J"},{"key":"814_CR51","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/hmg\/ddm080","volume":"16","author":"C Iaccarino","year":"2007","unstructured":"Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet. 2007;16:1319\u201326.","journal-title":"Hum Mol Genet"},{"key":"814_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/exnr.2000.7489","volume":"166","author":"NA Tatton","year":"2000","unstructured":"Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson\u2019s disease. Exp Neurol. 2000;166:29\u201343.","journal-title":"Exp Neurol"},{"key":"814_CR53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1196\/annals.1299.123","volume":"1010","author":"F Blandini","year":"2003","unstructured":"Blandini F, Mangiagalli A, Cosentino M, Marino F, Samuele A, Rasini E, et al. Peripheral markers of apoptosis in Parkinson\u2019s disease: the effect of dopaminergic drugs. Ann N Y Acad Sci. 2003;1010:675\u20138.","journal-title":"Ann N Y Acad Sci"},{"key":"814_CR54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1471-4159.2003.01522.x","volume":"84","author":"Z Jiang","year":"2003","unstructured":"Jiang Z, Zheng X, Rich KM. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem. 2003;84:273\u201381.","journal-title":"J Neurochem."},{"key":"814_CR55","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.18632\/oncotarget.1154","volume":"4","author":"U Liwak","year":"2013","unstructured":"Liwak U, Jordan LE, Von-Holt SD, Singh P, Hanson JE, Lorimer IA, et al. Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation. Oncotarget. 2013;4:1365\u201372.","journal-title":"Oncotarget."},{"key":"814_CR56","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/imr.12541","volume":"277","author":"B Tummers","year":"2017","unstructured":"Tummers B, Green DR. Caspase-8: regulating life and death. Immunol Rev. 2017;277:76\u201389.","journal-title":"Immunol Rev"},{"key":"814_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15466-8","volume":"11","author":"L Laurien","year":"2020","unstructured":"Laurien L, Nagata M, Schunke H, Delanghe T, Wiederstein JL, Kumari S, et al. Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation. Nat Commun. 2020;11:1747.","journal-title":"Nat Commun"},{"key":"814_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","volume":"148","author":"L Sun","year":"2012","unstructured":"Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213\u201327.","journal-title":"Cell."},{"key":"814_CR59","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2013.06.018","volume":"39","author":"JM Murphy","year":"2013","unstructured":"Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity. 2013;39:443\u201353.","journal-title":"Immunity."},{"key":"814_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16887-1","volume":"11","author":"AL Samson","year":"2020","unstructured":"Samson AL, Zhang Y, Geoghegan ND, Gavin XJ, Davies KA, Mlodzianoski MJ, et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nat Commun. 2020;11:3151.","journal-title":"Nat Commun"},{"key":"814_CR61","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41418-019-0457-8","volume":"27","author":"T Wang","year":"2020","unstructured":"Wang T, Perera ND, Chiam MDF, Cuic B, Wanniarachchillage N, Tomas D, et al. Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS. Cell Death Differ. 2020;27:1728\u201339.","journal-title":"Cell Death Differ"},{"key":"814_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15252\/emmm.201606566","volume":"9","author":"SH Yang","year":"2017","unstructured":"Yang SH, Lee DK, Shin J, Lee S, Baek S, Kim J, et al. Nec-1 alleviates cognitive impairment with reduction of Abeta and tau abnormalities in APP\/PS1 mice. EMBO Mol Med. 2017;9:61\u201377.","journal-title":"EMBO Mol Med"},{"key":"814_CR63","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nn.4608","volume":"20","author":"A Caccamo","year":"2017","unstructured":"Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, et al. Necroptosis activation in Alzheimer\u2019s disease. Nat Neurosci. 2017;20:1236\u201346.","journal-title":"Nat Neurosci"},{"key":"814_CR64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.immuni.2016.07.016","volume":"45","author":"S Alvarez-Diaz","year":"2016","unstructured":"Alvarez-Diaz S, Dillon CP, Lalaoui N, Tanzer MC, Rodriguez DA, Lin A, et al. The pseudokinase MLKL and the kinase RIPK3 have distinct roles in autoimmune disease caused by loss of death-receptor-induced apoptosis. Immunity. 2016;45:513\u201326.","journal-title":"Immunity."},{"key":"814_CR65","doi-asserted-by":"publisher","first-page":"E8788","DOI":"10.1073\/pnas.1714175114","volume":"114","author":"D Ofengeim","year":"2017","unstructured":"Ofengeim D, Mazzitelli S, Ito Y, DeWitt JP, Mifflin L, Zou C, et al. RIPK1 mediates a disease-associated microglial response in Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2017;114:E8788\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"814_CR66","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41418-019-0408-4","volume":"27","author":"M Onate","year":"2020","unstructured":"Onate M, Catenaccio A, Salvadores N, Saquel C, Martinez A, Moreno-Gonzalez I, et al. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease. Cell Death Differ. 2020;27:1169\u201385.","journal-title":"Cell Death Differ"},{"key":"814_CR67","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.celrep.2018.01.089","volume":"22","author":"A Iannielli","year":"2018","unstructured":"Iannielli A, Bido S, Folladori L, Segnali A, Cancellieri C, Maresca A, et al. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson\u2019s disease models. Cell Rep. 2018;22:2066\u201379.","journal-title":"Cell Rep."},{"key":"814_CR68","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493\u2013506.","journal-title":"Cell."},{"key":"814_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.94","volume":"2","author":"S Zhu","year":"2011","unstructured":"Zhu S, Zhang Y, Bai G, Li H. Necrostatin-1 ameliorates symptoms in R6\/2 transgenic mouse model of Huntington\u2019s disease. Cell Death Dis. 2011;2:e115.","journal-title":"Cell Death Dis"},{"key":"814_CR70","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.2174\/1570159X16666180302115544","volume":"16","author":"E Sekerdag","year":"2018","unstructured":"Sekerdag E, Solaroglu I, Gursoy-Ozdemir Y. Cell death mechanisms in stroke and novel molecular and cellular treatment options. Curr Neuropharmacol. 2018;16:1396\u2013415.","journal-title":"Curr Neuropharmacol"},{"key":"814_CR71","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11064-014-1510-0","volume":"40","author":"X Su","year":"2015","unstructured":"Su X, Wang H, Kang D, Zhu J, Sun Q, Li T, et al. Necrostatin-1 ameliorates intracerebral hemorrhage-induced brain injury in mice through inhibiting RIP1\/RIP3 pathway. Neurochem Res. 2015;40:643\u201350.","journal-title":"Neurochem Res"},{"key":"814_CR72","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/jcbfm.2010.72","volume":"31","author":"FJ Northington","year":"2011","unstructured":"Northington FJ, Chavez-Valdez R, Graham EM, Razdan S, Gauda EB, Martin LJ. Necrostatin decreases oxidative damage, inflammation, and injury after neonatal HI. J Cereb Blood Flow Metab. 2011;31:178\u201389.","journal-title":"J Cereb Blood Flow Metab"},{"key":"814_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.nbd.2014.04.002","volume":"68","author":"M Vieira","year":"2014","unstructured":"Vieira M, Fernandes J, Carreto L, Anuncibay-Soto B, Santos M, Han J, et al. Ischemic insults induce necroptotic cell death in hippocampal neurons through the up-regulation of endogenous RIP3. Neurobiol Dis. 2014;68:26\u201336.","journal-title":"Neurobiol Dis"},{"key":"814_CR74","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbcan.2019.01.006","volume":"1871","author":"X Qin","year":"2019","unstructured":"Qin X, Ma D, Tan YX, Wang HY, Cai Z. The role of necroptosis in cancer: a double-edged sword? Biochim Biophys Acta Rev Cancer. 2019;1871:259\u201366.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"814_CR75","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/carcin\/bgw032","volume":"37","author":"KD McCormick","year":"2016","unstructured":"McCormick KD, Ghosh A, Trivedi S, Wang L, Coyne CB, Ferris RL, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. Carcinogenesis. 2016;37:522\u20139.","journal-title":"Carcinogenesis."},{"key":"814_CR76","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/carcin\/bgt143","volume":"34","author":"Q Wang","year":"2013","unstructured":"Wang Q, Chen W, Xu X, Li B, He W, Padilla MT, et al. RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. Carcinogenesis. 2013;34:2119\u201328.","journal-title":"Carcinogenesis."},{"key":"814_CR77","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1158\/0008-5472.CAN-08-4079","volume":"69","author":"S Park","year":"2009","unstructured":"Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009;69:2809\u201316.","journal-title":"Cancer Res"},{"key":"814_CR78","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11060-020-03473-0","volume":"147","author":"GA Vergara","year":"2020","unstructured":"Vergara GA, Eugenio GC, Malheiros SMF, Victor EDS, Weinlich R. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping. J Neurooncol. 2020;147:587\u201394.","journal-title":"J Neurooncol"},{"key":"814_CR79","doi-asserted-by":"publisher","first-page":"821","DOI":"10.21037\/tcr.2019.05.01","volume":"8","author":"Y Dong","year":"2019","unstructured":"Dong Y, Sun Y, Huang Y, Dwarakanath B, Kong L, Lu JJ. Upregulated necroptosis-pathway-associated genes are unfavorable prognostic markers in low-grade glioma and glioblastoma multiforme. Transl Cancer Res. 2019;8:821\u20137.","journal-title":"Transl Cancer Res"},{"key":"814_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1029-8","volume":"18","author":"Y Gong","year":"2019","unstructured":"Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18:100.","journal-title":"Mol Cancer"},{"key":"814_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/cr.2013.169","volume":"24","author":"Y Ohsumi","year":"2014","unstructured":"Ohsumi Y. Historical landmarks of autophagy research. Cell Res. 2014;24:9\u201323.","journal-title":"Cell Res"},{"key":"814_CR82","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41418-019-0480-9","volume":"27","author":"Y Yang","year":"2020","unstructured":"Yang Y, Klionsky DJ. Autophagy and disease: unanswered questions. Cell Death Differ. 2020;27:858\u201371.","journal-title":"Cell Death Differ"},{"key":"814_CR83","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41556-018-0201-5","volume":"20","author":"J Doherty","year":"2018","unstructured":"Doherty J, Baehrecke EH. Life, death and autophagy. Nat Cell Biol. 2018;20:1110\u20137.","journal-title":"Nat Cell Biol"},{"key":"814_CR84","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/NEN.0b013e3182160690","volume":"70","author":"S Sasaki","year":"2011","unstructured":"Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2011;70:349\u201359.","journal-title":"J Neuropathol Exp Neurol"},{"key":"814_CR85","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.brainres.2007.06.045","volume":"1167","author":"N Morimoto","year":"2007","unstructured":"Morimoto N, Nagai M, Ohta Y, Miyazaki K, Kurata T, Morimoto M, et al. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res. 2007;1167:112\u20137.","journal-title":"Brain Res"},{"key":"814_CR86","doi-asserted-by":"publisher","first-page":"E8294","DOI":"10.1073\/pnas.1704294114","volume":"114","author":"ND Rudnick","year":"2017","unstructured":"Rudnick ND, Griffey CJ, Guarnieri P, Gerbino V, Wang X, Piersaint JA, et al. Distinct roles for motor neuron autophagy early and late in the SOD1(G93A) mouse model of ALS. Proc Natl Acad Sci USA. 2017;114:E8294\u2013303.","journal-title":"Proc Natl Acad Sci USA"},{"key":"814_CR87","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.1523\/JNEUROSCI.0800-08.2008","volume":"28","author":"B Boland","year":"2008","unstructured":"Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer\u2019s disease. J Neurosci. 2008;28:6926\u201337.","journal-title":"J Neurosci"},{"key":"814_CR88","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1080\/15548627.2016.1239003","volume":"12","author":"M Bordi","year":"2016","unstructured":"Bordi M, Berg MJ, Mohan PS, Peterhoff CM, Alldred MJ, Che S, et al. Autophagy flux in CA1 neurons of Alzheimer hippocampus: increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy. 2016;12:2467\u201383.","journal-title":"Autophagy."},{"key":"814_CR89","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.gde.2009.03.008","volume":"19","author":"J Hardy","year":"2009","unstructured":"Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics of Parkinson\u2019s syndromes: a critical review. Curr Opin Genet Dev. 2009;19:254\u201365.","journal-title":"Curr Opin Genet Dev."},{"key":"814_CR90","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.1523\/JNEUROSCI.5809-11.2012","volume":"32","author":"LG Friedman","year":"2012","unstructured":"Friedman LG, Lachenmayer ML, Wang J, He L, Poulose SM, Komatsu M, et al. Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain. J Neurosci. 2012;32:7585\u201393.","journal-title":"J Neurosci"},{"key":"814_CR91","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13024-016-0141-0","volume":"11","author":"MS Wold","year":"2016","unstructured":"Wold MS, Lim J, Lachance V, Deng Z, Yue Z. ULK1-mediated phosphorylation of ATG14 promotes autophagy and is impaired in Huntington\u2019s disease models. Mol Neurodegener. 2016;11:76.","journal-title":"Mol Neurodegener"},{"key":"814_CR92","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585\u201395.","journal-title":"Nat Genet"},{"key":"814_CR93","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/hmg\/ddu522","volume":"24","author":"M Kurosawa","year":"2015","unstructured":"Kurosawa M, Matsumoto G, Kino Y, Okuno M, Kurosawa-Yamada M, Washizu C, et al. Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington\u2019s model mice. Hum Mol Genet. 2015;24:1092\u2013105.","journal-title":"Hum Mol Genet"},{"key":"814_CR94","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.18632\/oncotarget.3018","volume":"6","author":"JS Lee","year":"2015","unstructured":"Lee JS, Oh E, Yoo JY, Choi KS, Yoon MJ, Yun CO. Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget. 2015;6:4051\u201365.","journal-title":"Oncotarget."},{"key":"814_CR95","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2017.10.017","volume":"184","author":"S Hombach-Klonisch","year":"2018","unstructured":"Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, Hamai A, et al. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Pharm Ther. 2018;184:13\u201341.","journal-title":"Pharm Ther"},{"key":"814_CR96","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.molonc.2015.04.016","volume":"9","author":"M Catalano","year":"2015","unstructured":"Catalano M, D\u2019Alessandro G, Lepore F, Corazzari M, Caldarola S, Valacca C, et al. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol Oncol. 2015;9:1612\u201325.","journal-title":"Mol Oncol"},{"key":"814_CR97","doi-asserted-by":"publisher","first-page":"20016","DOI":"10.18632\/oncotarget.7910","volume":"7","author":"L Jennewein","year":"2016","unstructured":"Jennewein L, Ronellenfitsch MW, Antonietti P, Ilina EI, Jung J, Stadel D, et al. Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas. Oncotarget. 2016;7:20016\u201332.","journal-title":"Oncotarget."},{"key":"814_CR98","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3390\/cancers11091374","volume":"11","author":"Y Kwon","year":"2019","unstructured":"Kwon Y, Kim M, Jung HS, Kim Y, Jeoung D. Targeting autophagy for overcoming resistance to anti-EGFR treatments. Cancers (Basel). 2019;11:1374.","journal-title":"Cancers (Basel)"},{"key":"814_CR99","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1158\/0008-5472.CAN-11-3831","volume":"72","author":"YL Hu","year":"2012","unstructured":"Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012;72:1773\u201383.","journal-title":"Cancer Res"},{"key":"814_CR100","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/onc.2016.333","volume":"36","author":"EE Mowers","year":"2017","unstructured":"Mowers EE, Sharifi MN, Macleod KF. Autophagy in cancer metastasis. Oncogene. 2017;36:1619\u201330.","journal-title":"Oncogene."},{"key":"814_CR101","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cmet.2017.04.004","volume":"25","author":"AC Kimmelman","year":"2017","unstructured":"Kimmelman AC, White E. Autophagy and tumor metabolism. Cell Metab. 2017;25:1037\u201343.","journal-title":"Cell Metab"},{"key":"814_CR102","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell."},{"key":"814_CR103","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1021\/acschembio.5b00245","volume":"10","author":"SJ Dixon","year":"2015","unstructured":"Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol. 2015;10:1604\u20139.","journal-title":"ACS Chem Biol"},{"key":"814_CR104","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91\u20138.","journal-title":"Nat Chem Biol"},{"key":"814_CR105","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell."},{"key":"814_CR106","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693\u20138.","journal-title":"Nature."},{"key":"814_CR107","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688\u201392.","journal-title":"Nature."},{"key":"814_CR108","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","volume":"6","author":"VAN Kraft","year":"2020","unstructured":"Kraft VAN, Bezjian CT, Pfeiffer S, Ringelstetter L, Muller C, Zandkarimi F, et al. GTP cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020;6:41\u201353.","journal-title":"ACS Cent Sci"},{"key":"814_CR109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1021\/acscentsci.7b00589","volume":"4","author":"R Shah","year":"2018","unstructured":"Shah R, Shchepinov MS, Pratt DA. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent Sci. 2018;4:387\u201396.","journal-title":"ACS Cent Sci."},{"key":"814_CR110","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/mp.2017.171","volume":"22","author":"QZ Tuo","year":"2017","unstructured":"Tuo QZ, Lei P, Jackman KA, Li XL, Xiong H, Li XL, et al. Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Mol Psychiatry. 2017;22:1520\u201330.","journal-title":"Mol Psychiatry"},{"key":"814_CR111","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nbd.2016.05.011","volume":"94","author":"B Do Van","year":"2016","unstructured":"Do Van B, Gouel F, Jonneaux A, Timmerman K, Gele P, Petrault M, et al. Ferroptosis, a newly characterized form of cell death in Parkinson\u2019s disease that is regulated by PKC. Neurobiol Dis. 2016;94:169\u201378.","journal-title":"Neurobiol Dis"},{"key":"814_CR112","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1021\/ja411006a","volume":"136","author":"R Skouta","year":"2014","unstructured":"Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136:4551\u20136.","journal-title":"J Am Chem Soc"},{"key":"814_CR113","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.redox.2017.01.021","volume":"12","author":"WS Hambright","year":"2017","unstructured":"Hambright WS, Fonseca RS, Chen L, Na R, Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017;12:8\u201317.","journal-title":"Redox Biol"},{"key":"814_CR114","doi-asserted-by":"publisher","first-page":"28097","DOI":"10.1074\/jbc.M115.680090","volume":"290","author":"L Chen","year":"2015","unstructured":"Chen L, Hambright WS, Na R, Ran Q. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem. 2015;290:28097\u2013106.","journal-title":"J Biol Chem"},{"key":"814_CR115","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.brainres.2018.09.012","volume":"1701","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Wu Y, Yuan S, Zhang P, Zhang J, Li H, et al. Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. Brain Res. 2018;1701:112\u201325.","journal-title":"Brain Res"},{"key":"814_CR116","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","volume":"337","author":"DR Crapper McLachlan","year":"1991","unstructured":"Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer\u2019s disease. Lancet. 1991;337:1304\u20138.","journal-title":"Lancet."},{"key":"814_CR117","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.neurobiolaging.2012.05.009","volume":"34","author":"C Guo","year":"2013","unstructured":"Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer\u2019s disease. Neurobiol Aging. 2013;34:562\u201375.","journal-title":"Neurobiol Aging"},{"key":"814_CR118","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.brainres.2017.09.019","volume":"1677","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, He ML. Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP\/PS1 mice. Brain Res. 2017;1677:86\u201392.","journal-title":"Brain Res"},{"key":"814_CR119","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3233\/JAD-209009","volume":"78","author":"SS Rao","year":"2020","unstructured":"Rao SS, Portbury SD, Lago L, Bush AI, Adlard PA. The iron chelator deferiprone improves the phenotype in a mouse model of tauopathy. J Alzheimers Dis. 2020;78:1783.","journal-title":"J Alzheimers Dis"},{"key":"814_CR120","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1089\/ars.2017.7493","volume":"29","author":"C Moreau","year":"2018","unstructured":"Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, et al. Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal. 2018;29:742\u20138.","journal-title":"Antioxid Redox Signal"},{"key":"814_CR121","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal. 2014;21:195\u2013210.","journal-title":"Antioxid Redox Signal"},{"key":"814_CR122","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bph.14881","volume":"177","author":"A Southon","year":"2020","unstructured":"Southon A, Szostak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, et al. Cu(II) (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br J Pharmacol. 2020;177:656\u201367.","journal-title":"Br J Pharmacol"},{"key":"814_CR123","first-page":"271","volume":"10","author":"S Nikseresht","year":"2020","unstructured":"Nikseresht S, Hilton JBW, Kysenius K, Liddell JR, Crouch PJ. Copper-ATSM as a treatment for ALS: support from mutant SOD1 models and beyond. Life (Basel). 2020;10:271.","journal-title":"Life (Basel)"},{"key":"814_CR124","first-page":"280","volume":"19","author":"D Rowe","year":"2018","unstructured":"Rowe D, Mathers S, Smith G, Windebank E, Rogers M-L, Noel K, et al. Modification of ALS disease progression in a phase 1 trial of CuATSM. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:280\u201381.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"814_CR125","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fcell.2020.00538","volume":"8","author":"HJ Liu","year":"2020","unstructured":"Liu HJ, Hu HM, Li GZ, Zhang Y, Wu F, Liu X, et al. Ferroptosis-related gene signature predicts glioma cell death and glioma patient progression. Front Cell Dev Biol. 2020;8:538.","journal-title":"Front Cell Dev Biol"},{"key":"814_CR126","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1172\/JCI99032","volume":"128","author":"B Hassannia","year":"2018","unstructured":"Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Invest. 2018;128:3341\u201355.","journal-title":"J Clin Invest"},{"key":"814_CR127","doi-asserted-by":"publisher","first-page":"BSR20193314","DOI":"10.1042\/BSR20193314","volume":"40","author":"R Yi","year":"2020","unstructured":"Yi R, Wang H, Deng C, Wang X, Yao L, Niu W, et al. Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition. Biosci Rep. 2020;40:BSR20193314.","journal-title":"Biosci Rep"},{"key":"814_CR128","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/CAD.0000000000000825","volume":"31","author":"X Gao","year":"2020","unstructured":"Gao X, Guo N, Xu H, Pan T, Lei H, Yan A, et al. Ibuprofen induces ferroptosis of glioblastoma cells via downregulation of nuclear factor erythroid 2-related factor 2 signaling pathway. Anticancer Drugs. 2020;31:27\u201334.","journal-title":"Anticancer Drugs"},{"key":"814_CR129","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7868\/S0869803113030065","volume":"53","author":"SD Ivanov","year":"2013","unstructured":"Ivanov SD, Semenov AL, Mikhelson VM, Kovan\u2019ko EG, Iamshanov VA. [Effects of iron ion additional introduction in radiation therapy of tumor-bearing animals]. Radiats Biol Radioecol. 2013;53:296\u2013303.","journal-title":"Radiats Biol Radioecol"},{"key":"814_CR130","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10517-015-2865-1","volume":"158","author":"SD Ivanov","year":"2015","unstructured":"Ivanov SD, Semenov AL, Kovan\u2019ko EG, Yamshanov VA. Effects of iron ions and iron chelation on the efficiency of experimental radiotherapy of animals with gliomas. Bull Exp Biol Med. 2015;158:800\u20133.","journal-title":"Bull Exp Biol Med"},{"key":"814_CR131","doi-asserted-by":"publisher","first-page":"74630","DOI":"10.18632\/oncotarget.11858","volume":"7","author":"T Sehm","year":"2016","unstructured":"Sehm T, Rauh M, Wiendieck K, Buchfelder M, Eyupoglu IY, Savaskan NE. Temozolomide toxicity operates in a xCT\/SLC7a11 dependent manner and is fostered by ferroptosis. Oncotarget. 2016;7:74630\u201347.","journal-title":"Oncotarget."},{"key":"814_CR132","doi-asserted-by":"publisher","first-page":"36021","DOI":"10.18632\/oncotarget.8651","volume":"7","author":"T Sehm","year":"2016","unstructured":"Sehm T, Fan Z, Ghoochani A, Rauh M, Engelhorn T, Minakaki G, et al. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. Oncotarget. 2016;7:36021\u201333.","journal-title":"Oncotarget."},{"key":"814_CR133","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41388-020-01622-3","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Kong Y, Ma Y, Ni S, Wikerholmen T, Xi K, et al. Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines. Oncogene. 2021;40:1425\u201339.","journal-title":"Oncogene"},{"key":"814_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19193-y","volume":"11","author":"PP Yee","year":"2020","unstructured":"Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.","journal-title":"Nat Commun"},{"key":"814_CR135","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660\u20135.","journal-title":"Nature."},{"key":"814_CR136","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature18590","volume":"535","author":"J Ding","year":"2016","unstructured":"Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016;535:111\u20136.","journal-title":"Nature."},{"key":"814_CR137","doi-asserted-by":"publisher","first-page":"e10248","DOI":"10.15252\/emmm.201810248","volume":"11","author":"S Voet","year":"2019","unstructured":"Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med. 2019;11:e10248.","journal-title":"EMBO Mol Med"},{"key":"814_CR138","doi-asserted-by":"publisher","first-page":"E6065","DOI":"10.1073\/pnas.1722041115","volume":"115","author":"BA McKenzie","year":"2018","unstructured":"McKenzie BA, Mamik MK, Saito LB, Boghozian R, Monaco MC, Major EO, et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc Natl Acad Sci USA. 2018;115:E6065\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"814_CR139","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/cdd.2011.164","volume":"19","author":"N Vanlangenakker","year":"2012","unstructured":"Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ. 2012;19:75\u201386.","journal-title":"Cell Death Differ."},{"key":"814_CR140","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-021-03218-7","volume":"591","author":"N Kayagaki","year":"2021","unstructured":"Kayagaki N, Kornfeld OS, Lee BL, Stowe IB, O\u2019Rourke K, Li Q, et al. NINJ1 mediates plasma membrane rupture during lytic cell death. Nature. 2021;591:131\u20136.","journal-title":"Nature"},{"key":"814_CR141","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1415","volume":"4","author":"J Vakkila","year":"2004","unstructured":"Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641\u20138.","journal-title":"Nat Rev Immunol"},{"key":"814_CR142","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1084\/jem.20181892","volume":"216","author":"DE Place","year":"2019","unstructured":"Place DE, Kanneganti TD. Cell death-mediated cytokine release and its therapeutic implications. J Exp Med. 2019;216:1474\u201386.","journal-title":"J Exp Med"},{"key":"814_CR143","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.immuni.2020.07.004","volume":"53","author":"M Doerflinger","year":"2020","unstructured":"Doerflinger M, Deng Y, Whitney P, Salvamoser R, Engel S, Kueh AJ, et al. Flexible usage and interconnectivity of diverse cell death pathways protect against intracellular infection. Immunity. 2020;53:533\u201347 e7.","journal-title":"Immunity."},{"key":"814_CR144","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41580-020-0270-8","volume":"21","author":"S Bedoui","year":"2020","unstructured":"Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020;21:678\u201395.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"814_CR145","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bbr.2008.09.040","volume":"196","author":"HS Kim","year":"2009","unstructured":"Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196:168\u201379.","journal-title":"Behav Brain Res"},{"key":"814_CR146","doi-asserted-by":"crossref","unstructured":"Howard R, Zubko O, Gray R, Bradley R, Harper E, Kelly L, et al. Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer\u2019s disease: the MADE phase II, three-arm RCT. Efficacy and Mechanism Evaluation. Southampton (UK); 2020.","DOI":"10.3310\/eme07020"},{"key":"814_CR147","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrd.2018.65","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard A. Microglia-targeted candidates push the Alzheimer drug envelope. Nat Rev Drug Discov. 2018;17:303\u20135.","journal-title":"Nat Rev Drug Discov"},{"key":"814_CR148","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919\u201330.","journal-title":"N Engl J Med"},{"key":"814_CR149","doi-asserted-by":"publisher","first-page":"10703","DOI":"10.1073\/pnas.0712034105","volume":"105","author":"AH Stegh","year":"2008","unstructured":"Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA. 2008;105:10703\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"814_CR150","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.biochem.69.1.217","volume":"69","author":"A Strasser","year":"2000","unstructured":"Strasser A, O\u2019Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217\u201345.","journal-title":"Annu Rev Biochem"},{"key":"814_CR151","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.cell.2007.11.027","volume":"131","author":"A Bergmann","year":"2007","unstructured":"Bergmann A. Autophagy and cell death: no longer at odds. Cell. 2007;131:1032\u20134.","journal-title":"Cell."},{"key":"814_CR152","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cdd.2008.150","volume":"16","author":"G Kroemer","year":"2009","unstructured":"Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3\u201311.","journal-title":"Cell Death Differ"},{"key":"814_CR153","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/neuonc\/nov104","volume":"17","author":"KM Field","year":"2015","unstructured":"Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 2015;17:1504\u201313.","journal-title":"Neuro Oncol"},{"key":"814_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5413-y","volume":"19","author":"P Lesueur","year":"2019","unstructured":"Lesueur P, Lequesne J, Grellard JM, Dugue A, Coquan E, Brachet PE, et al. Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer. 2019;19:198.","journal-title":"BMC Cancer"},{"key":"814_CR155","doi-asserted-by":"publisher","first-page":"e11119","DOI":"10.1097\/MD.0000000000011119","volume":"97","author":"J Mandrioli","year":"2018","unstructured":"Mandrioli J, D\u2019Amico R, Zucchi E, Gessani A, Fini N, Fasano A, et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore). 2018;97:e11119.","journal-title":"Medicine (Baltimore)"},{"key":"814_CR156","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.trci.2018.09.009","volume":"4","author":"CW Zhu","year":"2018","unstructured":"Zhu CW, Grossman H, Neugroschl J, Parker S, Burden A, Luo X, et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer\u2019s disease: a pilot study. Alzheimers Dement. 2018;4:609\u201316.","journal-title":"Alzheimers Dement."},{"key":"814_CR157","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","volume":"85","author":"RS Turner","year":"2015","unstructured":"Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383\u201391.","journal-title":"Neurology."},{"key":"814_CR158","doi-asserted-by":"publisher","first-page":"337","DOI":"10.7326\/0003-4819-144-5-200603070-00008","volume":"144","author":"J Sotelo","year":"2006","unstructured":"Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144:337\u201343.","journal-title":"Ann Intern Med"},{"key":"814_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep. 2017;7:1398.","journal-title":"Sci Rep."}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-021-00814-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-021-00814-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-021-00814-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T06:24:55Z","timestamp":1725171895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-021-00814-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":159,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1038\/s41418-021-00814-y","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DM and AS are employees of The Walter and Eliza Hall Institute, which receives milestone payments and royalties from Genentech and AbbVie for the development of ABT-199\/venetoclax. AS collaborates with Servier on the development of MCL-1-specific BH3 mimetic drugs for cancer therapy. JRL has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}